Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Porcine respiratory and reproductive syndrome virus
Laboratorios Hipra SA
QI09AD03
Porcine respiratory and reproductive syndrome virus
Lyophilisate and solvent for solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Pigs
Live Viral Vaccine
Authorized
2013-03-06
Revised: February 2022 AN: 00003/2021 & 00004/2021 Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Unistrain PRRS lyophilisate and solvent for suspension for injection for pigs. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose contains: Freeze-dried powder: Active substance: Live attenuated Porcine reproductive and respiratory syndrome virus (PRRSV), strain VP-046 BIS ………………………………………………………………….… 10 3.5 -10 5.5 CCID 50 (_cell culture infectious dose_) Solvent: Phosphate buffer solution. Excipients: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Lyophilisate: white to yellowish powder. Solvent: Homogeneous-clear solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Breeding females: For active immunisation of breeding females from farms affected with European PRRS virus to reduce reproductive disorders, incidence and duration of viraemia, transplacental virus transmission, virus tissue load and clinical signs in the offspring associated with infection with strains of PRRS virus. Under laboratory conditions, vaccination of females reduced the negative impact of PRRS virus infection on piglet performance (mortality and weight gain) within the first 28 days of life. Onset of immunity: 30 days after vaccination. Revised: February 2022 AN: 00003/2021 & 00004/2021 Page 2 of 9 Duration of immunity: 16 weeks after vaccination. Pigs from 4 weeks of age: For active immunisation of pigs from farms affected with European PRRS virus to reduce clinical signs associated with a PRRS virus infection, the incidence and duration of viraemia and the duration of virus shedding by infected animals. Under experimental conditions, it was demonstrated that vaccination reduces the virus tissue load in the lungs. Under field conditions, where a PRRSV infection occurred during the fattening period, a reduc Read the complete document